Int J Med Sci 2019; 16(3):424-442. doi:10.7150/ijms.30154

Review

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

Qing Zhang1✉, Shaobin Wang2, Junhui Chen1, Zhendong Yu3✉

1. Department of Minimally Invasive Intervention, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
2. Health Management Center of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
3. China Central Laboratory of Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.

Abstract

T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.

Keywords: Histone deacetylases (HDACs), T-cell lymphomas, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, combination therapy

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 2019; 16(3):424-442. doi:10.7150/ijms.30154. Available from http://www.medsci.org/v16p0424.htm